- Home
- SVII vs TCRX Comparison
SVII vs TCRX Comparison
Compare SVII & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVII
- TCRX
- Stock Information
- Founded
- SVII 2021
- TCRX 2018
- Country
- SVII United States
- TCRX United States
- Employees
- SVII N/A
- TCRX N/A
- Industry
- SVII Blank Checks
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- SVII Finance
- TCRX Health Care
- Exchange
- SVII Nasdaq
- TCRX Nasdaq
- Market Cap
- SVII 252.5M
- TCRX 257.5M
- IPO Year
- SVII 2022
- TCRX 2021
- Fundamental
- Price
- SVII $11.23
- TCRX $3.94
- Analyst Decision
- SVII
- TCRX Strong Buy
- Analyst Count
- SVII 0
- TCRX 5
- Target Price
- SVII N/A
- TCRX $11.40
- AVG Volume (30 Days)
- SVII 134.4K
- TCRX 263.4K
- Earning Date
- SVII 01-01-0001
- TCRX 11-12-2024
- Dividend Yield
- SVII N/A
- TCRX N/A
- EPS Growth
- SVII N/A
- TCRX N/A
- EPS
- SVII N/A
- TCRX N/A
- Revenue
- SVII N/A
- TCRX $9,362,000.00
- Revenue This Year
- SVII N/A
- TCRX N/A
- Revenue Next Year
- SVII N/A
- TCRX $3.10
- P/E Ratio
- SVII $12.50
- TCRX N/A
- Revenue Growth
- SVII N/A
- TCRX N/A
- 52 Week Low
- SVII $10.78
- TCRX $3.93
- 52 Week High
- SVII $11.70
- TCRX $9.69
- Technical
- Relative Strength Index (RSI)
- SVII 34.95
- TCRX 28.71
- Support Level
- SVII $11.20
- TCRX $5.03
- Resistance Level
- SVII $11.37
- TCRX $6.23
- Average True Range (ATR)
- SVII 0.05
- TCRX 0.41
- MACD
- SVII -0.04
- TCRX -0.15
- Stochastic Oscillator
- SVII 6.00
- TCRX 0.76
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.